Abivax Shares Drop 4.82% at Close, to 102.60 Euros
French biotech company Abivax closed the trading session on Friday, November 21, 2025, at 102.60 euros, down 4.82% from the previous day's price of 107.80 euros. This correction follows a notable week with a 14.77% increase, amidst a stable Parisian market with the CAC 40 slightly up by 0.02% at 7,982.65 points. Trading volumes remained limited with only 0.23% of the capital traded, indicating a restricted float.
Stock Performance Context
This Friday's decline is part of an exceptional stock performance for the company. Over the year, the stock has shown an impressive gain of 1,222.49% since the beginning of the year, also marking the best performance of the SBF 120 since January 1. Over three months, the increase reaches 73.9%, significantly higher than the CAC 40's annual performance of 10.89%. This upward trend originates from positive results in phase 3 ABTECT clinical trials for obefazimod, Abivax's flagship drug candidate in the treatment of ulcerative colitis. Insights from Wolfe Research indicating potential in Crohn's disease strengthen market sentiments towards positive anticipation. The stock is currently trading near its resistance threshold at 107.80 euros, while technical support is at 76.10 euros. Insider movements indicate some profit-taking: a significant sale of 590,877 shares for approximately 55.6 million euros was recorded, alongside a symbolic purchase of 35,456 shares. Sofinnova Partners crossed below the 10% voting rights threshold in Abivax on October 29, following a sale of shares off and on the market. A net short position representing 0.51% of the capital remains, indicating that some investors anticipate a correction.
Technical Analysis Overview
From a technical analysis standpoint, several indicators provide mixed signals. The RSI at 68 is in the high neutral zone, close to the overbought threshold, suggesting that the stock may enter a consolidation phase after its recent strong progression. The indicator confirms an upward momentum without signaling an oversold condition that would justify an immediate rebound. The stock is significantly above its 50-day (80.63 euros) and 200-day (35.56 euros) moving averages, demonstrating a solidly established upward trend. The widening gap between these two averages, from 44.67 to 44.85 points in recent sessions, confirms the acceleration of the trend. The MACD shows a positive setup with a MACD line at 5.50 above its signal line at 4.19, and a positive histogram of 1.31, reinforcing the medium-term bullish bias. The one-month volatility remains high at 18.86%, with an ATR of 3.44, reflecting significant fluctuations inherent to biotechs in clinical phases. The Beta of 2.25 highlights the title's heightened sensitivity to market variations. The Chaikin Money Flow indicator, positive at 0.05, indicates moderate buying flow, while the negative On Balance Volume at -227,901 suggests cautious accumulation by investors.
Analyst Consensus
The consensus among analysts, who follow the stock with five firms, shows an average price target of 100 euros, slightly below the current price, reflecting stretched valuations after the strong revaluation. An analyst emphasizes that Abivax, being a pre-commercialization biotech in a high-value therapeutic area, is very likely to be acquired by a pharmaceutical company. The company plans to submit an authorization request to the FDA in the second half of 2026, subject to positive results from the 44-week maintenance trial expected in the second quarter of 2026. These milestones are major catalysts for the stock in the coming months.
